You’re cruising through a GI pharm block in your Q-bank when you see octreotide pop up—and suddenly every answer choice looks kind of plausible. That’s exactly why this drug is so high-yield: it sits at the intersection of endocrine physiology, portal HTN management, and “classic” Step-style carcinoid/vipoma vignettes. Let’s walk through a vignette, nail the correct answer, and then dismantle each distractor like you would on test day.
Tag: GI > GI Pharmacology
The Clinical Vignette (Q-bank style)
A 58-year-old man with a history of alcohol use disorder and cirrhosis presents to the ED after vomiting a large amount of bright red blood. He is diaphoretic and confused. Vitals: T 36.8°C, BP 88/54, HR 124. Exam shows jaundice, ascites, and spider angiomas. Labs show Hgb 7.9 g/dL. He is intubated for airway protection, given IV fluids and blood products. Upper endoscopy is being arranged.
Which medication should be given now to reduce bleeding?
A. Omeprazole
B. Octreotide
C. Lactulose
D. Propranolol
E. Ursodeoxycholic acid
The Correct Answer: B. Octreotide
Why octreotide is the move here
This is a suspected esophageal variceal hemorrhage (cirrhosis + massive hematemesis + shock). In acute variceal bleeding, you don’t wait for endoscopy to start pharmacologic therapy that lowers portal venous inflow.
Octreotide is a somatostatin analog that:
- Decreases splanchnic (GI) blood flow
- Decreases portal venous pressure
- Decreases release of multiple GI hormones (including VIP, gastrin, insulin, glucagon)
High-yield Step framing
In acute variceal bleeding, think of a 3-pronged initial approach:
| Goal | What you do | USMLE buzzwords |
|---|---|---|
| Stabilize | Airway protection, volume resuscitation, transfuse PRBCs | “Intubated,” “shock,” “massive hematemesis” |
| Reduce portal pressure now | Octreotide (or terlipressin where available) | “Splanchnic vasoconstriction” |
| Prevent infection (improves mortality) | IV ceftriaxone (often tested!) | “Cirrhosis + GI bleed → antibiotics” |
Then you proceed with urgent endoscopy for band ligation (definitive control).
Core mechanism (testable in one line)
Somatostatin analog → ↓ splanchnic vasodilation → ↓ portal venous inflow → ↓ variceal bleeding.
Why Every Other Answer Choice Is Wrong (but tempting)
A. Omeprazole (PPI)
Why it tempts you: GI bleed = “give a PPI,” right?
Why it’s wrong here: PPIs are key for upper GI bleeding due to peptic ulcer disease and are often started empirically if etiology is unclear. But this vignette screams variceal bleed (cirrhosis stigmata + brisk hematemesis + shock). PPIs don’t meaningfully reduce portal pressures or variceal bleeding.
High-yield distinction
- Variceal bleed: octreotide + antibiotics + endoscopic banding
- Peptic ulcer bleed: IV PPI + endoscopic therapy (clips/epi/cautery)
C. Lactulose
Why it tempts you: He’s confused, and cirrhotics get hepatic encephalopathy.
Why it’s wrong here: In this vignette, the immediate life threat is hemorrhagic shock from variceal bleeding. Confusion can be from shock/hypoperfusion (or encephalopathy triggered by GI bleed), but lactulose does nothing to stop active bleeding.
What lactulose actually does (high-yield)
- Treats hepatic encephalopathy by trapping ammonia: in the gut
- Increases stool frequency → ammonia excretion
- Classic adverse effects: diarrhea, dehydration, electrolyte issues
Use it after stabilization if encephalopathy is a primary ongoing issue.
D. Propranolol (nonselective beta-blocker)
Why it tempts you: Nonselective beta-blockers are used for portal hypertension.
Why it’s wrong here: Propranolol is for prophylaxis, not for an actively bleeding, unstable patient.
- Acute bleeding: you want a rapid decrease in portal inflow via octreotide (and endoscopic control)
- Secondary prevention after stabilization: nonselective beta-blocker + repeat band ligation
High-yield mechanism
- blockade → ↓ cardiac output
- blockade → unopposed vasoconstriction in splanchnic circulation → ↓ portal flow
Test trap: Don’t pick propranolol when the patient is hypotensive/shocked—beta-blockade can worsen hemodynamics.
E. Ursodeoxycholic acid (ursodiol)
Why it tempts you: Cirrhosis/jaundice = “bile acid therapy?”
Why it’s wrong here: Ursodiol is used in specific cholestatic conditions, not for acute GI bleeding.
High-yield uses
- Primary biliary cholangitis (PBC): improves cholestasis markers
- Cholesterol gallstones: can dissolve small stones in select cases
- It does not treat portal HTN or varices.
Octreotide: High-Yield Uses You’ll See Again
1) Variceal bleeding (GI system classic)
- Acute management to reduce portal pressures
- Often paired with endoscopic band ligation and ceftriaxone
2) Carcinoid syndrome
Tumor secretes serotonin and other vasoactive substances →
- Flushing
- Diarrhea
- Bronchospasm, wheezing
Octreotide reduces hormone release and controls symptoms.
3) VIPoma (WDHA syndrome)
Watery Diarrhea, Hypokalemia, Achlorhydria (VIP increases intestinal secretion)
Octreotide decreases VIP-mediated secretion.
4) Acromegaly
Somatostatin analog inhibits GH release (also: pegvisomant = GH receptor antagonist).
Adverse Effects & Testable Details
| Effect | Why it happens | How it shows up |
|---|---|---|
| Gallstones | ↓ CCK → ↓ gallbladder contraction | RUQ pain, biliary colic; “cholelithiasis” association |
| GI symptoms | Broad inhibition of GI hormones | Abdominal pain, nausea, diarrhea (sometimes steatorrhea) |
| Glucose disturbances | ↓ insulin and ↓ glucagon | Hypo- or hyperglycemia (variable) |
| Bradycardia | Autonomic/endocrine effects | Low HR, especially with IV use |
Board-style pearl: If a patient on octreotide develops RUQ pain after weeks/months, think gallstones.
Rapid-Fire Pattern Recognition (What to pick when)
- Cirrhosis + massive hematemesis + shock → Octreotide (plus antibiotics + endoscopy)
- PUD bleed clues (NSAIDs, epigastric pain, melena) → IV PPI
- Confusion + cirrhosis (asterixis, elevated ammonia) → Lactulose (± rifaximin)
- Portal HTN prophylaxis (no active bleed) → Propranolol/Nadolol
- PBC (middle-aged woman, pruritus, antimitochondrial Ab) → Ursodiol
Key Takeaways (the “why this question exists” recap)
- Octreotide is the acute pharmacologic bridge for suspected variceal hemorrhage because it lowers splanchnic blood flow and portal pressure.
- Distractors often represent real GI therapies—but for a different time course (prophylaxis vs acute) or different diagnosis (PUD vs varices, encephalopathy vs hemorrhage).
- Know the octreotide triad of Step uses: varices, carcinoid syndrome, VIPoma (plus acromegaly as a common bonus).